- Home
- HHS vs NRSN Comparison
HHS vs NRSN Comparison
Compare HHS & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HHS
- NRSN
- Stock Information
- Founded
- HHS 1923
- NRSN 2017
- Country
- HHS United States
- NRSN Israel
- Employees
- HHS N/A
- NRSN N/A
- Industry
- HHS Advertising
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- HHS Consumer Discretionary
- NRSN Health Care
- Exchange
- HHS Nasdaq
- NRSN Nasdaq
- Market Cap
- HHS 26.9M
- NRSN 29.8M
- IPO Year
- HHS N/A
- NRSN 2021
- Fundamental
- Price
- HHS $2.85
- NRSN $1.10
- Analyst Decision
- HHS
- NRSN Buy
- Analyst Count
- HHS 0
- NRSN 2
- Target Price
- HHS N/A
- NRSN $14.00
- AVG Volume (30 Days)
- HHS 20.7K
- NRSN 302.0K
- Earning Date
- HHS 11-10-2025
- NRSN 12-17-2025
- Dividend Yield
- HHS N/A
- NRSN N/A
- EPS Growth
- HHS N/A
- NRSN N/A
- EPS
- HHS N/A
- NRSN N/A
- Revenue
- HHS $166,841,000.00
- NRSN N/A
- Revenue This Year
- HHS $6.54
- NRSN N/A
- Revenue Next Year
- HHS N/A
- NRSN N/A
- P/E Ratio
- HHS N/A
- NRSN N/A
- Revenue Growth
- HHS N/A
- NRSN N/A
- 52 Week Low
- HHS $2.33
- NRSN $0.80
- 52 Week High
- HHS $6.20
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- HHS 44.36
- NRSN 52.19
- Support Level
- HHS $2.73
- NRSN $0.89
- Resistance Level
- HHS $2.87
- NRSN $1.28
- Average True Range (ATR)
- HHS 0.15
- NRSN 0.10
- MACD
- HHS 0.02
- NRSN 0.02
- Stochastic Oscillator
- HHS 75.64
- NRSN 57.36
About HHS Harte-Hanks Inc.
Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.